Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer

R. F. H. Walter, P. Rozynek, S. Casjens, R. Werner, F. D. Mairinger, E. J. M. Speel, A. Zur Hausen, S. Meier, J. Wohlschlaeger, D. Theegarten, T. Behrens, K. W. Schmid, T. Bruning, G. Johnen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numbere0195716
Pages (from-to)1
Number of pages17
JournalPLOS ONE
Volume13
Issue number5
DOIs
Publication statusPublished - 31 May 2018

Keywords

  • PROMOTER METHYLATION
  • NEUROENDOCRINE TUMORS
  • METAANALYSIS
  • SUPPRESSOR
  • CDKN2A
  • LINE1
  • DNA
  • TUMOR-SUPPRESSOR

Cite this

Walter, R. F. H., Rozynek, P., Casjens, S., Werner, R., Mairinger, F. D., Speel, E. J. M., Zur Hausen, A., Meier, S., Wohlschlaeger, J., Theegarten, D., Behrens, T., Schmid, K. W., Bruning, T., & Johnen, G. (2018). Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer. PLOS ONE, 13(5), 1. [e0195716]. https://doi.org/10.1371/journal.pone.0195716